

# ESMO-Magnitude of Clinical Benefit Scale version 1.1

Annals of Oncology

28, 2340-2366

DOI: [10.1093/annonc/mdx310](https://doi.org/10.1093/annonc/mdx310)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. <i>Annals of Oncology</i> , 2017, 28, 2633-2647.	0.6	87
2	Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 ( <a href="http://www.esmo.org/Guidelines/Gastrointestinal-Cancers">www.esmo.org/Guidelines/Gastrointestinal-Cancers</a> ). <i>Annals of Oncology</i> , 2017, 28, iv157.	0.6	13
3	Guideposts on the journey to value. <i>Annals of Oncology</i> , 2017, 28, 2325-2326.	0.6	0
4	Cancer drugs in LMICs: cheap but unaffordable. <i>Oncotarget</i> , 2017, 8, 89425-89426.	0.8	7
5	Cancer immunotherapy and the value of cure. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 268-270.	12.5	126
6	Developing Anticancer Drugs in Orphan Molecular Entities – A Paradigm under Construction. <i>New England Journal of Medicine</i> , 2018, 378, 763-765.	13.9	18
7	Reply to the letter to the editor –ESMO-MCBS v1.1: statistical and patient relevant shortcomings™ by Emprechtinger et al.. <i>Annals of Oncology</i> , 2018, 29, 1335-1338.	0.6	0
8	Reply to the letter to the editor –Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies™. <i>Annals of Oncology</i> , 2018, 29, 774-775.	0.6	1
9	Reply to the letter to the editor –Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?™ by Del Paggio. <i>Annals of Oncology</i> , 2018, 29, 521-522.	0.6	1
10	Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies. <i>Annals of Oncology</i> , 2018, 29, 773-774.	0.6	8
11	ESMO-MCBS v1.1: statistical and patient-relevant shortcomings. <i>Annals of Oncology</i> , 2018, 29, 1070-1071.	0.6	2
12	Hans Christian Andersen and the Value of New Cancer Treatments. <i>Journal of the National Cancer Institute</i> , 2018, 110, 441-442.	3.0	6
13	The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. <i>Annals of Oncology</i> , 2018, 29, 1588-1593.	0.6	5
14	Treatment of advanced HER2-positive breast cancer: 2018 and beyond. <i>Cancer Treatment Reviews</i> , 2018, 67, 10-20.	3.4	107
15	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1142-1143.	3.0	1
16	Toxicity adjustment in the ESMO-MCBS: a gestalt approach?. <i>Annals of Oncology</i> , 2018, 29, 520-521.	0.6	2
17	Results From a Health Insurer's Clinical Pathway Program in Breast Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e711-e721.	2.5	8
18	Global Breast Cancer Research: Moving Forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 441-450.	1.8	36

#	ARTICLE	IF	CITATIONS
19	Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky037.	1.4	4
20	Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky050.	1.4	7
21	Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?. <i>Annals of Translational Medicine</i> , 2018, 6, S120-S120.	0.7	3
22	Precision oncology: separating the wheat from the chaff. <i>ESMO Open</i> , 2018, 3, e000446.	2.0	37
23	Access to Affordable Breast Cancer Care in Eastern Europe. <i>Current Breast Cancer Reports</i> , 2018, 10, 170-178.	0.5	4
24	Choosing wisely in oncology: necessity and obstacles. <i>ESMO Open</i> , 2018, 3, e000382.	2.0	13
25	Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?. <i>Cancer Management and Research</i> , 2018, Volume 10, 5423-5431.	0.9	1
26	A review of guidelines for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1556-S1563.	0.6	64
27	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. <i>JAMA Oncology</i> , 2018, 4, 1610.	3.4	27
28	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
30	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. <i>Annals of Oncology</i> , 2018, 29, 2288-2295.	0.6	57
31	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. <i>European Journal of Cancer</i> , 2018, 104, 160-168.	1.3	14
32	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	1.3	37
33	Soft tissue and visceral sarcomas: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
34	A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. <i>Clinical Cancer Research</i> , 2018, 24, 4968-4975.	3.2	12
35	This is a call to oncologists for action. <i>Clinical and Translational Oncology</i> , 2018, 20, 1493-1501.	1.2	1
36	Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer â€œ ESMO-MCBS scores. <i>Cancer Treatment Reviews</i> , 2018, 69, 233-242.	3.4	9
37	Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?. <i>ESMO Open</i> , 2018, 3, e000392.	2.0	0

#	ARTICLE	IF	CITATIONS
38	Patient-reported outcomes with nivolumab in advanced solid cancers. <i>Cancer Treatment Reviews</i> , 2018, 70, 75-87.	3.4	19
39	Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. <i>Annals of Oncology</i> , 2018, 29, 1718-1726.	0.6	103
40	4th ESOâ€ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
41	Quality of life with talazoparib versus physicianâ€™s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1939-1947.	0.6	107
42	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. <i>JAMA Oncology</i> , 2018, 4, 1437.	3.4	1
43	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2018, 29, 1895-1902.	0.6	424
44	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Frameworkâ€™Reply. <i>JAMA Oncology</i> , 2018, 4, 1438.	3.4	1
45	Early Access in Oncology: Why Is It Needed?. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031985707.	0.2	3
46	The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1065-1069.	5.1	54
47	Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Nonâ€™Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale. <i>JAMA Network Open</i> , 2019, 2, e196803.	2.8	13
48	Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications. <i>Value in Health</i> , 2019, 22, 884-890.	0.1	15
49	Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. <i>JAMA Oncology</i> , 2019, 5, 1807.	3.4	1
50	When is off-label off-road?. <i>Annals of Oncology</i> , 2019, 30, 1536-1538.	0.6	12
51	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of â‰¥1% by the USA Food and Drug Administration. <i>Annals of Oncology</i> , 2019, 30, 1686-1688.	0.6	20
52	The Use of (Network) Meta-Analysis in Clinical Oncology. <i>Frontiers in Oncology</i> , 2019, 9, 822.	1.3	38
53	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
54	Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1856-1883.	0.6	592
55	Flawed evidence underpins approval of new cancer drugs. <i>BMJ: British Medical Journal</i> , 2019, 366, I5399.	2.4	7

#	ARTICLE	IF	CITATIONS
56	Value and Values in Cancer Care. Assessing the Benefit of Treatment in Patients with Advanced Cancer. <i>Oncology Research and Treatment</i> , 2019, 42, 35-40.	0.8	4
57	Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 351-352.	0.6	3
58	Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors. <i>Frontiers in Oncology</i> , 2019, 9, 453.	1.3	23
59	Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 1395-1397.	0.6	35
60	&lt;p&gt;Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
61	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	0.6	1,241
62	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 374-387.	1.8	19
63	The Impact of Big Data Research on Practice, Policy, and Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e167-e175.	1.8	18
64	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e152-e166.	1.8	12
65	Value-Added Decisions in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 122-131.	1.8	5
66	More options for adjuvant treatment of HER2â€positive breast cancer: How to choose wisely?. <i>International Journal of Cancer</i> , 2019, 145, 2901-2906.	2.3	10
67	Assessment of Whether the American Society of Clinical Oncologyâ€™s Value Framework and the European Society for Medical Oncologyâ€™s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit. <i>JAMA Oncology</i> , 2019, 5, 1188.	3.4	19
68	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
69	ESMOâ€™ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
70	ESMOâ€™ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
71	Two-way traffic: aligning expectations with current realities in oncology. <i>Mid-term ESMO Presidency considerations. ESMO Open</i> , 2019, 4, e000494.	2.0	0
72	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019, 8, 1584-1593.	1.3	18
73	Insert: Therapeutic Operative Procedures Suggested by an Expert: From Clinical Trials to Clinical Practice. , 2019, , 137-142.		0

#	ARTICLE	IF	CITATIONS
74	Pre-reimbursement: early assessment for coverage decisions. Wiener Medizinische Wochenschrift, 2019, 169, 254-262.	0.5	7
75	Value assessment frameworks in oncology: championing concordance through shared standards. Annals of Oncology, 2019, 30, 505-506.	0.6	2
76	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	0.8	101
77	ESMO-MCBS: setting the record straight – Authors' reply. Lancet Oncology, The, 2019, 20, e193.	5.1	1
78	Global Disparities: Can the World Afford Cancer?. , 2019, , 79-94.		2
79	Causes, Consequences, and Control of High Cancer Drug Prices. , 2019, , 39-57.		1
80	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	1.8	150
81	Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 1060-1061.	1.8	1
82	ESMO-MCBS: setting the record straight. Lancet Oncology, The, 2019, 20, e192.	5.1	2
83	Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology. International Journal of Technology Assessment in Health Care, 2019, 35, 56-63.	0.2	13
84	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 706-720.	0.6	750
85	Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. ESMO Open, 2019, 4, e000483.	2.0	31
86	Innovative oncology products: time to revisit the strategy development?. ESMO Open, 2019, 4, e000571.	2.0	2
88	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
89	Expectation and Preferences with Palliative Systemic Therapy in Recurrent Gliomas. , 2019, 04, .		0
90	Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. Breast Care, 2019, 14, 373-381.	0.8	8
91	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. Immuno-Oncology Technology, 2019, 4, 1-7.	0.2	2
92	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. Breast, 2019, 48, S81-S84.	0.9	1

#	ARTICLE	IF	CITATIONS
93	Clinical Benefit in the Treatment of Patients with Early Breast Cancer. <i>Breast</i> , 2019, 48, S115-S118.	0.9	1
94	Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 717-723.	0.7	14
95	Management of drainage for malignant ascites in gynaecological cancer. <i>The Cochrane Library</i> , 2019, 12, CD007794.	1.5	7
96	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	0.6	214
97	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 241-255.	12.5	56
98	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 34-43.	0.6	166
99	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 19-33.	0.6	165
100	Weighing false hope in population anticancer drug decision making. <i>Annals of Oncology</i> , 2019, 30, 10-11.	0.6	4
101	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
102	Association between progression-free survival and patients' quality of life in cancer clinical trials. <i>International Journal of Cancer</i> , 2019, 144, 1746-1751.	2.3	62
103	The promise of ESCAT: a new system for evaluating cancer drug-target pairs. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 147-148.	12.5	9
104	Cancer Drug Toxicity: Moving from Patient to Survivor. <i>Cancer Treatment and Research</i> , 2019, 171, 107-118.	0.2	3
105	Targeting CDK4/6 pathways and beyond in breast cancer. <i>Breast</i> , 2019, 43, 8-17.	0.9	22
106	How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. <i>Journal of Cancer Education</i> , 2020, 35, 545-556.	0.6	1
107	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	2.6	17
108	What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 48-52.	1.6	5
109	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	2.0	13
110	Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. <i>Clinical Therapeutics</i> , 2020, 42, 34-43.	1.1	18

#	ARTICLE	IF	CITATIONS
111	Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018. <i>Health Policy</i> , 2020, 124, 261-267.	1.4	9
112	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020, 139, 47-54.	0.9	28
113	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
114	MET inhibitors in cancer: pitfalls and challenges. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 73-85.	1.9	16
115	“Some sort of fantasy land”: A qualitative investigation of appropriate prescribing in cancer care. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 747-754.	0.9	1
116	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. <i>ESMO Open</i> , 2020, 5, e000681.	2.0	5
117	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	1.9	6
119	Introduction by the Guest Editors. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 279-280.	1.0	0
120	Recent Update to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2020, 31, 1265-1266.	0.6	20
121	Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1462-1475.	0.6	359
122	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
123	Cancer Drugs in Asian Populations. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 323-329.	1.0	1
124	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1291-1305.	0.6	591
125	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3889.	1.0	35
126	Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. <i>EClinicalMedicine</i> , 2020, 25, 100458.	3.2	10
127	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	2.0	19
128	TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?. <i>Lancet Oncology, The</i> , 2020, 21, 1002-1003.	5.1	0
129	A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma “To Know, Then to Measure. <i>Frontiers in Oncology</i> , 2020, 10, 1076.	1.3	1

#	ARTICLE	IF	CITATIONS
130	Reply to S.G. Chun et al. Journal of Clinical Oncology, 2020, 38, 3457-3458.	0.8	0
131	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 2020, 5, e000826.	2.0	60
132	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open, 2020, 5, e000793.	2.0	113
133	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 2020, 5, e000804.	2.0	61
134	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open, 2020, 5, e000820.	2.0	96
135	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. ESMO Open, 2020, 5, e000827.	2.0	18
136	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	1.4	4
137	Clinical development of cell therapies for cancer: The regulators' perspective. European Journal of Cancer, 2020, 138, 41-53.	1.3	9
138	Incorporating Value-Based Care Into Oncology. Cancer Journal (Sudbury, Mass ), 2020, 26, 311-322.	1.0	9
139	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open, 2020, 5, e000743.	2.0	7
140	Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration. BMC Cancer, 2020, 20, 823.	1.1	9
141	Applying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in a Pandemic. JAMA Oncology, 2020, 6, 1429.	3.4	12
142	Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters. Journal of Thoracic Oncology, 2020, 15, 1394-1396.	0.5	0
143	Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development. Cancers, 2020, 12, 3577.	1.7	4
144	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 3611.	1.7	30
145	Value in Oncology: Beware Putting Lipstick on a Pig. JCO Oncology Practice, 2020, 16, 439-441.	1.4	0
146	Applying the ASCO and European Society for Medical Oncology Value Frameworks to Nasopharyngeal Cancer Treatments: Is Adding Induction Chemotherapy or Adjuvant Chemotherapy to Concurrent Chemoradiotherapy Worthwhile?. JCO Oncology Practice, 2020, 16, e1386-e1396.	1.4	1
147	Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). Cancers, 2020, 12, 3265.	1.7	9

#	ARTICLE	IF	CITATIONS
148	Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitorsâ€”2020 Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3520.	1.0	16
149	Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology Residents: A National Survey. <i>JCO Global Oncology</i> , 2020, 6, 1674-1683.	0.8	30
150	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2017675.	2.8	20
151	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Nonâ€”Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2530-2542.	0.8	47
152	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	2.3	17
153	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. <i>Supportive Care in Cancer</i> , 2020, 28, 4589-4612.	1.0	156
154	Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. <i>Drug Discovery Today</i> , 2020, 25, 1580-1584.	3.2	3
155	Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1406-1408.	0.5	10
156	Realâ€”world outcomes of advanced melanoma patients not represented in phase <sc>III</sc> trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
157	The global imperative to make cancer medications affordable. <i>Lancet Oncology</i> , The, 2020, 21, 609-610.	5.1	2
158	Immunotherapy in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 187.	1.3	66
159	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus â€” Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	0.8	25
160	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	0.9	111
161	Mature Versus Registration Studies of Immunoâ€”Oncology Agents: Does Value Improve With Time?. <i>JCO Oncology Practice</i> , 2020, 16, e779-e790.	1.4	3
162	Required efficacy for novel therapies in BCGâ€”unresponsive nonâ€”muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?. <i>Cancer Medicine</i> , 2020, 9, 3287-3296.	1.3	6
163	Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. <i>JCO Oncology Practice</i> , 2020, 16, e298-e305.	1.4	6
164	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , 2020, 23, 689-698.	2.7	16
165	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485

#	ARTICLE	IF	CITATIONS
166	The global landscape of drug development for kidney cancer. <i>Cancer Treatment Reviews</i> , 2020, 89, 102061.	3.4	5
167	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 588-600.	0.8	1
168	Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology. <i>Pharmaceutical Medicine</i> , 2020, 34, 103-112.	1.0	6
169	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124.	157.7	123
170	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâ€™ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020, 31, 334-351.	0.6	138
171	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 451-469.	0.6	34
172	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	3.4	17
173	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 191-201.	0.6	70
174	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. <i>Value in Health</i> , 2020, 23, 319-327.	0.1	15
175	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. <i>Annals of Oncology</i> , 2020, 31, 310-317.	0.6	105
176	Prices and clinical benefit of cancer drugs in the USA and Europe: a costâ€™benefit analysis. <i>Lancet Oncology</i> , The, 2020, 21, 664-670.	5.1	126
177	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 844-860.	0.6	571
178	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	1.4	23
179	EHA evaluation of the ESMOâ€™Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
180	Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplishedâ€™What is Next?. <i>HemaSphere</i> , 2020, 4, e354.	1.2	0
181	Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. <i>Current Medical Research and Opinion</i> , 2021, 37, 59-70.	0.9	5
182	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188487.	3.3	16
183	Reprint of â€™Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€™. <i>Oral Oncology</i> , 2021, 113, 105042.	0.8	18

#	ARTICLE	IF	CITATIONS
184	COVID-19 and systemic anticancer therapy: exploiting uncertainty. <i>Lancet Oncology</i> , The, 2021, 22, 3-5.	5.1	2
185	Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e191.	1.1	1
186	Quantitative Approaches to Therapeutic Decision Making in Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00846.	1.4	0
187	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
188	ASCO virtual meeting 2020: highlights head and neck cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 62-65.	0.3	0
189	Quality of in Older Patients with Cancer. , 2021, , 1-8.		0
190	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	2.0	35
191	SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2021-002692.	0.5	1
192	Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?. <i>Journal of Clinical Medicine</i> , 2021, 10, 746.	1.0	1
193	Assessment of Food and Drug Administrationâ€™ and European Medicines Agencyâ€™ Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life. <i>JAMA Network Open</i> , 2021, 4, e2033004.	2.8	23
194	Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 651-660.	3.3	33
195	Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3139.	1.2	4
196	Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1422-1428.	3.0	1
197	Radium-223 in the Modern Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Health of Man</i> , 2020, , 71-75.	0.1	0
198	The use of â€˜added benefitâ€™™ to determine the price of new anti-cancer drugs in France, 2004â€™2017. <i>European Journal of Cancer</i> , 2021, 145, 11-18.	1.3	13
199	Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 636561.	1.3	3
200	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
201	Editorial: Advances in the Pathogenesis and Therapeutic Strategies for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 647809.	1.3	5

#	ARTICLE	IF	CITATIONS
202	Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. <i>Cancer Treatment Reviews</i> , 2021, 94, 102167.	3.4	8
203	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 988-1000.	1.2	23
204	Lung Cancer in the Netherlands. <i>Journal of Thoracic Oncology</i> , 2021, 16, 355-365.	0.5	11
205	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	1.8	9
206	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. <i>JAMA Oncology</i> , 2021, 7, 379.	3.4	81
207	Patients' access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100050.	3.0	4
208	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. <i>Current Oncology</i> , 2021, 28, 1518-1527.	0.9	1
209	Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. <i>JAMA Internal Medicine</i> , 2021, 181, 499.	2.6	28
211	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837.	7.7	32
212	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 439-451.	0.6	101
213	The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?. <i>Health Policy</i> , 2021, 125, 593-601.	1.4	11
215	Financial Counseling Is Associated with Reduced Financial Difficulty Scores in Head and Neck Cancer Patients Treated with Radiation Therapy. <i>Cancers</i> , 2021, 13, 2516.	1.7	11
217	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee. <i>Gynecologic Oncology</i> , 2021, 161, 502-507.	0.6	3
218	Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas. <i>JAMA Oncology</i> , 2021, 7, 759.	3.4	18
220	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	2.0	37
221	Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1. <i>Acta Oncologica</i> , 2021, 60, 1225-1232.	0.8	2
222	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021, 150, 203-210.	1.3	5
223	Twelve years of European cancer drug approval – a systematic investigation of the ‘magnitude of clinical benefit’. <i>ESMO Open</i> , 2021, 6, 100166.	2.0	13

#	ARTICLE	IF	CITATIONS
224	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 801-805.	0.6	235
225	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
226	Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. <i>Annals of Oncology</i> , 2021, 32, 839-853.	0.6	204
227	Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 92.	2.3	8
229	Clinical benefit of systemic therapies for recurrent ovarian cancerâ€”ESMO-MCBS scores. <i>ESMO Open</i> , 2021, 6, 100229.	2.0	5
230	Has the Current Oncology Value Paradigm Forgotten Patientsâ€™ Time?. <i>JAMA Oncology</i> , 2021, 7, 1757.	3.4	17
231	Skip pattern approach toward the early access of innovative anticancer drugs. <i>ESMO Open</i> , 2021, 6, 100227.	2.0	1
232	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , 2021, 32, 1496-1510.	0.6	42
233	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.	1.5	15
234	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>Radiotherapy and Oncology</i> , 2022, 169, 114-123.	0.3	9
235	An urgent call to raise the bar in oncology. <i>British Journal of Cancer</i> , 2021, 125, 1477-1485.	2.9	34
236	Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation. <i>Clinical Oncology</i> , 2022, 34, 28-35.	0.6	12
237	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	4
238	Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 40, 101130.	3.2	16
239	Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. <i>Annals of Oncology</i> , 2021, 32, 1190-1191.	0.6	0
240	What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. <i>Value in Health</i> , 2022, 25, 302-317.	0.1	11
241	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. <i>JAMA Oncology</i> , 2021, 7, e212026.	3.4	46
242	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	1.3	8

#	ARTICLE	IF	CITATIONS
243	Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. <i>Annals of Oncology</i> , 2021, 32, 1637-1642.	0.6	137
244	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 1511-1519.	0.6	113
245	Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. <i>European Urology Oncology</i> , 2021, 4, 1011-1012.	2.6	2
246	Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	0.6	213
247	Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptorâ€“positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. <i>European Journal of Cancer</i> , 2021, 156, 70-82.	1.3	14
248	Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 1300-1303.	0.6	41
249	Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	16
250	Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. <i>Lancet Oncology</i> , The, 2019, 20, e112-e123.	5.1	40
251	Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy. <i>Breast Care</i> , 2021, 16, 500-506.	0.8	3
252	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. <i>Oncotarget</i> , 2020, 11, 399-408.	0.8	12
253	The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 170-182.	0.4	7
254	Expert-Based Strategies to Improve Access to Cancer Therapeutics at the Hospital Level. <i>Global Journal on Quality and Safety in Healthcare</i> , 2018, 1, 6-12.	0.1	3
255	Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1489-1496.	2.3	3
256	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 278-285.	2.3	12
258	New Drugs Development. <i>UNIPA Springer Series</i> , 2021, , 281-287.	0.1	0
260	Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 117-125.	2.3	4
261	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , 2021, 12, 754390.	1.6	3
262	Targeting the value of targeted therapy. <i>Oncotarget</i> , 2017, 8, 90612-90613.	0.8	1

#	ARTICLE	IF	CITATIONS
264	Improving Clinical Trial Design in Gastrointestinal Oncology. , 2019, , 493-507.		0
266	A multi-stakeholder approach in optimising patientsâ€™ needs in the benefit assessment process of new metastatic breast cancer treatments. Breast, 2020, 52, 78-87.	0.9	7
267	Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?. European Respiratory Journal, 2021, 58, 2101637.	3.1	2
268	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	0.8	1
269	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. JCO Oncology Practice, 2020, 16, 53-54.	1.4	1
270	360 Health Analysis (H360) â€“ A Proposal for an Integrated Vision of Breast Cancer in Portugal. The Journal of Breast Health, 2020, 16, 91-98.	0.4	2
271	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	0.6	454
272	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. European Journal of Cancer, 2021, 159, 154-166.	1.3	19
273	Considerations for the Management of Women with Breast Cancer during the COVID-19 Pandemic. Indian Journal of Cardiovascular Disease in Women WINCARS, 2020, 5, 260-263.	0.1	1
274	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
275	Quality-of-life methodology in hormone receptorâ€“positive advanced breast cancer: Current tools and perspectives for the future. Cancer Treatment Reviews, 2022, 102, 102321.	3.4	4
276	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Current Oncology, 2021, 28, 4894-4928.	0.9	0
277	Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ††. Annals of Oncology, 2022, 33, 129-142.	0.6	77
278	Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of Comparative Effectiveness Research, 2022, 11, 109-120.	0.6	6
279	Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 244-258.	0.6	211
280	Preâ€approval and postâ€approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 2022, 88, 2169-2179.	1.1	5
281	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. Cancer Management and Research, 2021, Volume 13, 8457-8471.	0.9	10
282	Examining the association between oncology drug clinical benefit and the time to public reimbursement. Cancer Medicine, 2022, 11, 380-391.	1.3	6

#	ARTICLE	IF	CITATIONS
283	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. <i>ESMO Open</i> , 2021, 6, 100304.	2.0	14
284	Quality of Life in Older Patients with Cancer. , 2021, , 4101-4107.		0
285	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	2.0	15
287	Progression-free survival 2: Is it ready for prime time?. <i>Cancer</i> , 2022, 128, 1361-1362.	2.0	1
289	Cancer outcome research – a European challenge Part II: Opportunities and priorities. <i>Molecular Oncology</i> , 2022, 16, 2300-2311.	2.1	1
290	WHO-ESMO collaboration in cancer control: policies into action to save lives. <i>ESMO Open</i> , 2022, 7, 100373.	2.0	2
291	ABC6 Consensus: Assessment by a Group of German Experts. <i>Breast Care</i> , 2022, 17, 90-100.	0.8	6
292	Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience. <i>ESMO Open</i> , 2022, 7, 100362.	2.0	8
293	New EU regulation on health technology assessment of cancer medicines. <i>Lancet Oncology</i> , The, 2022, 23, e58.	5.1	4
294	Is cabozantinib the common answer to all radioiodine-refractory differentiated thyroid cancers?. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 194.	0.1	1
295	Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program. <i>Annals of Oncology</i> , 2022, , .	0.6	4
296	Breast Cancer – Essential news of current guidelines. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	0
297	Medical Affairs and Innovative Medicinal Product Strategy Development. <i>Pharmaceutical Medicine</i> , 2022, 36, 71.	1.0	1
298	Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021. <i>Current Oncology</i> , 2022, 29, 1919-1931.	0.9	3
299	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	1.4	8
300	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
301	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. <i>Current Oncology</i> , 2022, 29, 2530-2538.	0.9	1
302	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103649.	2.0	9

#	ARTICLE	IF	CITATIONS
303	Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study. BMC Medical Research Methodology, 2021, 21, 282.	1.4	0
304	The value of anticancer drugs – a regulatory view. Nature Reviews Clinical Oncology, 2022, 19, 207-215.	12.5	14
306	Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model. JAMA Network Open, 2021, 4, e2139573.	2.8	8
307	Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We Optimize Care?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 501-510.	1.8	1
308	Prognostic Value of Systemic Inflammatory Response Markers in Patients Undergoing Neoadjuvant Chemotherapy and Gastrectomy for Advanced Gastric Cancer in the Eastern European Population. Cancers, 2022, 14, 1997.	1.7	9
309	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Network Open, 2022, 5, e224361.	2.8	2
310	Applicability of ESMO-MCBS and ESCAT for molecular tumor boards. Memo - Magazine of European Medical Oncology, 2022, 15, 190-195.	0.3	4
311	Cancer treatments should benefit patients: a common-sense revolution in oncology. Nature Medicine, 2022, 28, 617-620.	15.2	14
312	ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Annals of Oncology, 2022, 33, 674-684.	0.6	44
313	Advanced hepatocellular carcinoma: Impact of systemic treatments on health-related quality of life and patient-reported outcomes. Liver Cancer International, 0, , .	0.2	1
314	An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?. Nature Reviews Clinical Oncology, 2022, 19, 486-492.	12.5	14
317	Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. Pharmacoeconomics, 2022, 40, 623-631.	1.7	3
318	Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals of Oncology, 2022, 33, 702-712.	0.6	24
319	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast, 2022, , .	0.9	2
320	Clinical Benefit Scales and Trial Design: Some Statistical Issues. Journal of the National Cancer Institute, 2022, 114, 1222-1227.	3.0	1
321	Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. International Journal of Cancer, 2022, 151, 1345-1354.	2.3	5
322	An integrated valuation model for payer and investor. Journal of Market Access & Health Policy, 2022, 10, .	0.8	0
323	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice, 2022, 18, e1522-e1532.	1.4	16

#	ARTICLE	IF	CITATIONS
324	Clinical benefit of cancer drugs approved in Switzerland 2010–2019. PLoS ONE, 2022, 17, e0268545.	1.1	2
325	Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 860-877.	0.6	154
326	Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. European Urology, 2023, 83, 352-360.	0.9	3
327	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 2022, 14, 3193.	1.7	9
328	A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Study. Value in Health, 2022, , .	0.1	0
329	In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
330	The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS. BMC Health Services Research, 2022, 22, .	0.9	3
331	Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 992-1004.	0.6	145
332	Listening to the Patient Voice Adds Value to Cancer Clinical Trials. Journal of the National Cancer Institute, 2022, 114, 1323-1332.	3.0	10
333	Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 1005-1020.	0.6	313
335	Resilience index improves prediction of 1-year decreased quality of life in breast cancer. Journal of Cancer Survivorship, 2023, 17, 759-768.	1.5	11
336	Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials Led by High-Income Countries. JAMA Network Open, 2022, 5, e2227252.	2.8	23
337	Value-Based Care in Systemic Therapy: The Way Forward. Current Oncology, 2022, 29, 5792-5799.	0.9	3
338	Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020. JAMA Network Open, 2022, 5, e2225973.	2.8	17
339	Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Current Oncology, 2022, 29, 5774-5791.	0.9	10
340	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO Open, 2022, 7, 100560.	2.0	1
341	New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer, 2022, 174, 261-276.	1.3	8
342	Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. The Lancet Global Health, 2022, 10, e1860-e1866.	2.9	15

#	ARTICLE	IF	CITATIONS
343	Challenges in integrating molecular profiles into clinical cancer care. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
344	Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. Journal of Clinical Oncology, 2023, 41, 222-232.	0.8	58
345	Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis. Clinical and Translational Oncology, 2023, 25, 555-559.	1.2	1
347	Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care. Frontiers in Oncology, 0, 12, .	1.3	2
348	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 10-32.	0.6	316
349	Reforming the World Health Organization's Essential Medicines List. JAMA - Journal of the American Medical Association, 2022, 328, 1807.	3.8	5
350	Salivary gland cancer: ESMO's European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open, 2022, 7, 100602.	2.0	30
351	Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC. Lung Cancer, 2022, 174, 36-44.	0.9	4
352	Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 127-140.	0.6	119
353	Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open, 2023, 8, 100604.	2.0	5
354	Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. European Journal of Cancer, 2023, 180, 158-179.	1.3	9
355	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology, 2022, 18, 3769-3782.	1.1	11
356	Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. Annals of Oncology, 2023, 34, 431-439.	0.6	7
357	Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports, 2022, 12, .	1.6	0
358	ESMO's EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease. Annals of Oncology, 2023, 34, 247-250.	0.6	5
360	The COVID-19 explorer: An integrated, whole patient knowledge model of COVID-19 disease. Frontiers in Molecular Medicine, 0, 2, .	0.6	2
361	Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Frontiers in Medicine, 0, 9, .	1.2	4
362	EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 2023, 25, 813-826.	0.6	24

#	ARTICLE	IF	CITATIONS
363	Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 358-376.	0.6	94
364	Association Between Age and Survival Trends in Advanced Non-“Small Cell Lung Cancer After Adoption of Immunotherapy. <i>JAMA Oncology</i> , 2023, 9, 334.	3.4	15
365	Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. <i>Journal of Clinical Oncology</i> , 2023, 41, 2350-2361.	0.8	23
366	Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211489.	1.4	3
367	Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020. <i>JAMA Network Open</i> , 2023, 6, e2253438.	2.8	2
368	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 339-357.	0.6	118
369	Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.4	5
370	Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. <i>European Urology</i> , 2024, 85, 293-300.	0.9	2
371	Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. <i>Annals of Oncology</i> , 2023, 34, 557-563.	0.6	10
372	From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. <i>Lancet Oncology</i> , The, 2023, 24, e150-e160.	5.1	6
373	Competency-Based Workforce Development and Education in Global Oncology. <i>Current Oncology</i> , 2023, 30, 1760-1775.	0.9	3
374	ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling “ a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. <i>BMC Cancer</i> , 2023, 23, .	1.1	5
375	The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
377	Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study. , 2023, 2, e000021.		2
378	Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries. <i>ESMO Open</i> , 2023, 8, 101208.	2.0	2
379	Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 789-801.	0.9	1
380	Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions. <i>OncoTargets and Therapy</i> , 0, Volume 16, 249-259.	1.0	2
381	Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. <i>ESMO Open</i> , 2023, 8, 101209.	2.0	1

#	ARTICLE	IF	CITATIONS
382	Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2023, 39, .	0.2	0
383	Modern cancer trials still lack information about QoL impacts on patients. , 2023, 2, e000062.		1
384	Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
388	Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 527-542.	12.5	13
414	Cancer Among the Elderly. , 2023, , 1-31.		0